We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HMN:NYSEHorace Mann Educators Corporation Analysis

Data as of 2026-04-08 - not real-time

$43.96

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Horace Mann is trading just above its 20‑day and 50‑day moving averages at $43.96, yet remains below the 200‑day average, signaling a short‑term pullback within a longer‑term downtrend. The MACD has turned bullish with a positive histogram, while the RSI sits at 60, indicating modest upward momentum but no overbought alarm. Support around $41.29 and resistance near $44.31 frame the next price action, and a decreasing volume trend suggests waning short‑term enthusiasm. With a beta of only 0.27 and 30‑day volatility under 20%, the stock exhibits low market‑risk sensitivity. Valuation metrics are compelling: a trailing P/E of 11.3 is well under the industry average of 16.8, and the discounted cash‑flow model points to a fair value of roughly $51, implying about 17% upside. Dividend sustainability looks strong, highlighted by a 3% quarterly increase to $0.36 per share, a 3.28% yield and a modest 36% payout ratio supported by solid free cash flow. Recent insider buying and an upcoming earnings release add a layer of confidence, though the company’s high debt‑to‑equity ratio tempers enthusiasm.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bullish MACD but bearish trend direction
  • Decreasing volume indicating limited near‑term buying pressure
  • Attractive dividend yield and recent dividend increase

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF implied upside of ~17% and P/E well below industry average
  • Sustainable dividend with low payout ratio and strong cash flow
  • Insider buying and upcoming earnings release suggesting confidence

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Stable insurance business with low beta and modest volatility
  • Consistent dividend growth and solid ROE around 12%
  • Value orientation with a significant valuation gap to fair value

Key Metrics & Analysis

Financial Health

Revenue Growth6.30%
Profit Margin9.53%
P/E Ratio11.3
ROE11.70%
ROA1.00%
Debt/Equity110.13
P/B Ratio1.2
Op. Cash Flow$553.2M
Free Cash Flow$197.1M
Industry P/E16.8

Technical Analysis

TrendBearish
RSI60.2
Support$41.29
Resistance$44.31
MA 20$42.56
MA 50$43.04
MA 200$44.10
MACDBullish
VolumeDecreasing
Fear & Greed Index84.89

Valuation

Fair Value$51.28
Target Price$51.50
Upside/Downside17.15%
GradeUndervalued
TypeBlend
Dividend Yield3.28%

Risk Assessment

Beta0.27
Volatility18.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.